SensoPath Technologies is focused on design and synthesis of traditional thiol linkers and our patented dendrimer molecules used to produce remarkably stable self-assembled monolayers (SAMs) that are resistant to nonspecific binding in gold-based biosensors. These tethers are designed to enhance sensitivity, selectivity, specificity and stability and reproducibility in gold-based sensor and imaging applications. They are used for reduction of non-specific binding to gold surfaces. Antibodies, peptides, enzymes, carbohydrate-terminated dendrimers, DNA or RNA aptamers that will recognize specific ligands can be immobilized on self-assembled monolayers (SAMs) consisting of a tether molecule specifically designed for a gold-based sensor surface. In addition, the company has developed a new laser-based outpatient technology for the noninvasive treatment of solid cancerous tumors (photodynamic therapy or âPDTâ) that can replace the standard surgery/chemo/radiation regimen that most cancer patients must endur
